未找到相关数据
Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
被引：0
作者：
Petrylak, Daniel Peter
Shore, Neal D.
Bennamoun, Mostefa
Ratta, Raffaele
Piulats, Josep M.
Li, Ben
Schloss, Charles
Fizazi, Karim
机构：
[1] Yale Univ, Smilow Canc Hosp, New Haven, CT USA
[2] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[3] Inst Mutualiste Montsouris, Paris, France
[4] Hop Foch, Suresnes, France
[5] Catalan Canc Inst, Barcelona, Spain
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Gustave Roussy, Villejuif, France
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS262
引用
收藏
页数：1
相关论文